Several financial analysts have recently revised their price targets for Corvus Pharmaceuticals (NASDAQ: CRVS). On January 29, 2026, Mizuho set a new price target of $30.00 for the company. Earlier, on January 22, 2026, Jefferies Financial Group increased its price target from $13.00 to $42.00.
These updates reflect changing perspectives on Corvus Pharmaceuticals’ potential market performance based on recent developments and financial data.
**Why this matters**
Price target revisions can influence investor sentiment and trading activity. Higher targets may indicate increased confidence in the company’s growth prospects, while new targets provide updated benchmarks for evaluating stock value.
Source: NewsData